Differential Clinical Profiles, Exercise Responses, and Outcomes Associated With Existing HFpEF Definitions.
heart failure
heart failure, diastolic
stroke volume
Journal
Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763
Informations de publication
Date de publication:
30 07 2019
30 07 2019
Historique:
pubmed:
28
5
2019
medline:
25
4
2020
entrez:
29
5
2019
Statut:
ppublish
Résumé
Heart failure with preserved ejection fraction (HFpEF) is common, yet there is currently no consensus on how to define HFpEF according to various society and clinical trial criteria. How clinical and hemodynamic profiles of patients vary across definitions is unclear. We sought to determine clinical characteristics, as well as physiologic and prognostic implications of applying various criteria to define HFpEF. We examined consecutive patients with chronic exertional dyspnea (New York Heart Association class II to IV) and ejection fraction ≥50% referred for comprehensive cardiopulmonary exercise testing with invasive hemodynamic monitoring. We applied societal and clinical trial HFpEF definitions and compared clinical profiles, exercise responses, and cardiovascular outcomes. Of 461 patients (age 58±15 years, 62% women), 416 met American College of Cardiology/American Heart Association (ACC/AHA), 205 met European Society of Cardiology (ESC), and 55 met Heart Failure Society of America (HFSA) criteria for HFpEF. Clinical profiles and exercise capacity varied across definitions, with peak oxygen uptake of 16.2±5.2 (ACC/AHA), 14.1±4.2 (ESC), and 12.7±3.1 mL·kg Use of different HFpEF classifications variably enriches for future cardiovascular events, but at the expense of not including up to 85% of individuals with physiologic evidence of HFpEF. Comprehensive phenotyping of patients with suspected heart failure highlights the limitations and heterogeneity of current HFpEF definitions and may help to refine HFpEF subgrouping to test therapeutic interventions.
Sections du résumé
BACKGROUND
Heart failure with preserved ejection fraction (HFpEF) is common, yet there is currently no consensus on how to define HFpEF according to various society and clinical trial criteria. How clinical and hemodynamic profiles of patients vary across definitions is unclear. We sought to determine clinical characteristics, as well as physiologic and prognostic implications of applying various criteria to define HFpEF.
METHODS
We examined consecutive patients with chronic exertional dyspnea (New York Heart Association class II to IV) and ejection fraction ≥50% referred for comprehensive cardiopulmonary exercise testing with invasive hemodynamic monitoring. We applied societal and clinical trial HFpEF definitions and compared clinical profiles, exercise responses, and cardiovascular outcomes.
RESULTS
Of 461 patients (age 58±15 years, 62% women), 416 met American College of Cardiology/American Heart Association (ACC/AHA), 205 met European Society of Cardiology (ESC), and 55 met Heart Failure Society of America (HFSA) criteria for HFpEF. Clinical profiles and exercise capacity varied across definitions, with peak oxygen uptake of 16.2±5.2 (ACC/AHA), 14.1±4.2 (ESC), and 12.7±3.1 mL·kg
CONCLUSIONS
Use of different HFpEF classifications variably enriches for future cardiovascular events, but at the expense of not including up to 85% of individuals with physiologic evidence of HFpEF. Comprehensive phenotyping of patients with suspected heart failure highlights the limitations and heterogeneity of current HFpEF definitions and may help to refine HFpEF subgrouping to test therapeutic interventions.
Identifiants
pubmed: 31132875
doi: 10.1161/CIRCULATIONAHA.118.039136
pmc: PMC6684250
mid: NIHMS1532018
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-365Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL140224
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL131029
Pays : United States
Organisme : NHLBI NIH HHS
ID : K08 HL111210
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL138260
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL142809
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL134893
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
N Engl J Med. 2008 Dec 4;359(23):2456-67
pubmed: 19001508
Eur Heart J. 2009 Oct;30(20):2493-537
pubmed: 19713419
Circ Heart Fail. 2010 Sep;3(5):588-95
pubmed: 20543134
J Card Fail. 2010 Jun;16(6):e1-194
pubmed: 20610207
Circulation. 2011 Dec 6;124(23):2491-501
pubmed: 22064591
Eur Heart J. 2012 Jul;33(14):1787-847
pubmed: 22611136
J Heart Lung Transplant. 2012 Sep;31(9):913-33
pubmed: 22884380
Circ Heart Fail. 2013 Mar;6(2):184-92
pubmed: 23258572
JAMA. 2013 Mar 27;309(12):1268-77
pubmed: 23478662
Circulation. 2013 Oct 15;128(16):e240-327
pubmed: 23741058
Circulation. 2013 Sep 24;128(13):1470-9
pubmed: 24060943
Curr Heart Fail Rep. 2013 Dec;10(4):401-10
pubmed: 24078336
N Engl J Med. 2014 Apr 10;370(15):1383-92
pubmed: 24716680
Eur Heart J. 2014 Oct 21;35(40):2797-815
pubmed: 25104786
Circ Heart Fail. 2014 Sep;7(5):740-51
pubmed: 25122186
Eur Heart J. 2014 Nov 21;35(44):3103-12
pubmed: 25161181
Circulation. 2015 Jan 20;131(3):269-79
pubmed: 25398313
Circulation. 2015 Jan 6;131(1):34-42
pubmed: 25406305
J Am Coll Cardiol. 2015 Apr 28;65(16):1668-1682
pubmed: 25908073
J Am Coll Cardiol. 2015 Oct 13;66(15):1672-82
pubmed: 26449137
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
JACC Heart Fail. 2017 Jul;5(7):471-482
pubmed: 28662936
Circulation. 2018 Jan 9;137(2):148-161
pubmed: 28993402
Circulation. 2018 Jan 23;137(4):364-375
pubmed: 29142012
Eur Respir J. 2017 Nov 22;50(5):
pubmed: 29167297
JACC Heart Fail. 2018 Feb;6(2):117-126
pubmed: 29413366
Circ Heart Fail. 2018 May;11(5):e004750
pubmed: 29695381
Circulation. 2018 Aug 28;138(9):861-870
pubmed: 29792299
Eur Heart J. 2018 Aug 7;39(30):2822-2824
pubmed: 29939237